Abstract

Case Report

Scintigraphic non-invasive diagnosis of amyloid cardiomyopathy

Laroussi Mohamed-Salem*, Tomás E Rodríguez-Locarno, Tatiana Moreno-Monsalve, Isabel Castellón-Sánchez, José F Contreras-Gutiérrez and Antonia Claver-Valderas

Published: 04 October, 2019 | Volume 4 - Issue 3 | Pages: 156-158

Amyloidosis encompasses a heterogeneous group of disorders, characterized by extracellular deposition of insoluble abnormal amyloid aggregates, due to a failure in protein quality control. Cardiac amyloidosis is a disorder in which proteins misfold and deposit as amyloid fibrils that infiltrate the myocardial extracellular space [1].

Transthyretin (ATTR) and light chain (AL) are the most frequent types of cardiac amyloidosis. Transthyretin is a protein mainly synthesized by the liver, it may be hereditary or acquired from either wild-type (ATTRwt) or mutant (ATTRm) amyloid [2]. Cardiomyopathy is a common manifestation of ATTR amyloidosis with a particularly poor life expectancy of 2 to 6 years after diagnosis [3]. Although considered rare, the prevalence of this serious disease is likely underestimated because symptoms can be non-specific, and diagnosis largely relies on amyloid detection in tissue biopsies.

Read Full Article HTML DOI: 10.29328/journal.jccm.1001058 Cite this Article Read Full Article PDF

Keywords:

Computed tomography; DM; Coronary artery; Atherosclerosis

References

  1. Singh V, Falk R, Di Carli MF, Kijewski M, Rapezzi C, et al. State-of-the-art radionuclide imaging in cardiac transthyretin amyloidosis. J Nucl Cardiol. 2019; 26: 158-173. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/30569412
  2. Falk RH. Diagnosis and management of the cardiac amyloidoses. Circulation. 2005; 112: 2047-2060. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/16186440
  3. Patel KS, Hawkins PN. Cardiac amyloidosis: where are we today? J Intern Med. 2015; 278: 126-144. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/26077367
  4. Maurer MS, Bokhari S, Damy T, Dorbala S, Drachman BM, et al. Expert Consensus Recommendations for the Suspicion and Diagnosis of Transthyretin Cardiac Amyloidosis. Circ Heart Fail. 2019; 12: e006075. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/31480867
  5. Mohamed-Salem L, Santos-Mateo JJ, Sanchez-Serna J, Hernández-Vicente Á, Reyes-Marle R, et al. Prevalence of wild type ATTR assessed as myocardial uptake in bone scan in the elderly population. Int J Cardiol. 2017; 270: 192-196. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/29903517
  6. Mohamed-Salem L, Moreno-Monsalve T, Castellón-Sánchez MI, Claver-Valderas MA, Pascual-Figal DA. Non-biopsy diagnosis of familial amyloid cardiomyopathy. J Nucl Cardiol. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/30945209
  7. Haro-del F, Sánchez A, Gómez M, García P, Salas-Antón C, et al. Role of cardiac scintigraphy with 99mTC-DPD in the discrimination of the cardiac amyloidosis subtype. Rev Esp Cardiol. 2012; 65: 440-446.
  8. Zhao L, Tian Z, Fang Q. Diagnostic accuracy of cardiovascular magnetic resonance for patients with suspected cardiac amyloidosis: a systematic review and meta-analysis. BMC Cardiovascular Disorders. 2016; 16: 12. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/27267362
  9. Brownrigg J, Lorenzini M, Lumley M, Elliott P. Diagnostic performance of imaging investigations in detecting and differentiating cardiac amyloidosis: a systematic review and meta-analysis. ESC Heart Failure. 2019.
  10. Ertz MA, Benson MD, Dyck PJ, Grogan M, Coelho T, et al. Diagnosis, prognosis, and therapy of transthyretin amyloidosis. J Am Coll Cardiol. 2015; 66: 2451-2466. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/26610878
  11. Gillmore JD, Maurer MS, Falk RH, Merlini G, Damy T, et al. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation. 2016; 133: 2404-2412. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/27143678

Figures:

Figure 1

Figure 1

Figure 1

Figure 2

Similar Articles

Recently Viewed

Read More

Most Viewed

Read More